



ACTIVITY DESCRIPTION FORM (ADF)

Accreditation Council for Pharmacy Education

135 S. LaSalle Street, Suite 4100 Chicago, IL 60603-4810

Phone (312) 664-3575 Fax (312) 664-7008 <http://www.acpe-accredit.org>

UNIVERSAL ACTIVITY NUMBER (UAN): 0864-9999-24-040-H01-P

Provider Name: CPE Consultants, LLC

Cancel

Cosponsor(s): 9999 Joint Providership (H)

Activity Type: Knowledge

Activity Title: Mast Cell Activation Disease: An Exploration of the Complexities of Diagnosis, Treatment, and Co-Morbidities

Learning Objectives:
(Pharmacists)

At the completion of this activity, the participant will be able to:
Participants will explore the signs, symptoms, diagnostic criteria, and laboratory testing for Mast Cell Activation Disease (MCAD).
? Participants will gain a basic understanding of the immunology related to MCAD, the appropriate laboratory testing and appropriate interventions.
? Participants will investigate the role of histamine intolerance in mast cell activation as well as a unique phenotype by exploring the histamine catabolism pathway, genetic SNPs in this pathway and the metabolomic findings.
? Participants will understand the co-morbid conditions found in MCAD including Ehlers-Danlos Syndrome, dysautonomia, and mannose binding lectin deficiency.
? Participants will investigate the various treatments for MCAD including both pharmacological and functional medicine interventions including dietary change, micronutrient supplementation, polyphenols, and botanicals.
? Participants will develop an understanding of the psychological and neurotransmitter findings that are often found in MCAD patients as well as tools for assessment and intervention.

Activity Length: 2 **Contact Hours Or** 0.2 **CEUs.**

Target Audience: Pharmacists

Home Study Format(s): Web-based

Keyword(s): Immunology
Interventions
Laboratory
Nutrition

Initial Release Date: 06/04/2024

Planned Expiration Date: 06/04/2027

Originally Submitted By: Cheryl Reese

Submission Date: 06/04/2024

Last Modified By: Cheryl Reese

Modification Date: 06/04/2024